Get started
Work

OA03.03 Nivolumab (NIVO) + ipilimumab (IPI) Versus Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment for Advanced Non-Small Cell Lung Cancer (aNSCLC): 3-year Update from CheckMate 227 Part 1

Year: 2021
Type: conference-abstract
DOI: 10.1016/j.jtho.2020.10.023
Authors: S.S. Ramalingam, T.E. Ciuleanu, A. Pluzanski, J.-S. Lee, M. Schenker, R.B. Caro, K.H. Lee, B. Zurawski, C. Audigier-Valette, M. Provencio, H. Linardou, S.-W. Kim, H. Borghaei, M.D. Hellmann, K.J. O'Byrne, L.G. Paz-Ares, M. Reck, F.E. Nathan, J.R. Brahmer
Institutions: Emory University, Winship Cancer Institute, Institute of Oncology Prof. Dr. Ion Chiricuta, The Maria Sklodowska-Curie National Research Institute of Oncology, Seoul National University Bundang Hospital, Romanian Society of Nephrology, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Chungbuk National University, Chungbuk National University Hospital, Metropolitan Hospital, Asan Medical Center, Fox Chase Cancer Center, Memorial Sloan Kettering Cancer Center, Princess Alexandra Hospital, Hospital Universitario 12 De Octubre, German Center for Lung Research, LungenClinic Grosshansdorf, Bristol-Myers Squibb (United States), Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W3119218182
Cites:
Cited by: 2
Related to: 10